Possible add-on to insulin
LIRAGLUTIDE, a GLP-1 receptor agonist used in Europe and the US for the treatment of type 2 diabetes, may help patients with type 1 diabetes on insulin achieve optimal blood glucose control, early research suggests.
The observational trial of the injectable drug, which is usually used as add-on treatment in type 2 diabetes, involved 14 patients.
At the start of the study, all patients were “well-controlled”, but adding liraglutide to insulin therapy reduced glycaemic excursions and ultimately reduced the amount of insulin needed.
Improvements occurred within 1–2 days and reversed just as rapidly when liraglutide was discontinued. Patients also experienced a reduction in appetite and food intake while body weight was significantly reduced in the eight patients who took the drug for 24 weeks.
Liraglutide is TGA approved in Australia and currently before the PBAC for use as add-on treatment in type 2